PSMA is abundantly expressed on the surface of prostate cancer cells and within the neovasculature of other solid tumors, with limited expression in most normal tissues, establishing the basis for selective targeting of PCa lesions with PSMA-targeted agents. Here, FOLH1 is linked to posterior cortical atrophy.